Harrow: Position for Market Share Gains in U.S. Ophthalmics as Commercial Engine Scales
Harrow is moving from niche compounding toward a broad ophthalmic platform. Management reaffirmed 2025 revenue of $270-$280M, is doubling multiple sales forces, and is integrating Melt Pharmaceuticals to extend procedural sedation reach. With heavy short interest and near-term technical oversold signals, this is a tradeable long targeting a re-rati…